Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Stopped early · Phase 2
Conditions studied: Cancer
In brief
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving antithymocyte globulin together with clofarabine and rituximab works in treating patients after an unsuccessful stem cell transplant.
Key facts
- Study ID
- NCT00617929
- Run by
- Masonic Cancer Center, University of Minnesota
- People needed
- 12
- Starts
- 2008-01-01
- Expected to finish
- 2015-10-01
- Last updated by the study team
- 2017-12-28
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Masonic Cancer Center at University of Minnesota — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.